Alterity Therapeutics Limited

Alterity said it had no revenue for the period. It reported an operating loss of $8.6 million and a net operating cash outflow of $7.3 million, both described as in line with expectations and budget. Cash on hand was $35 million at December 31, supported by a $35 million capital raising that was fully subscribed. Looking ahead, management said ATH434 Phase II preparations are progressing to plan, with trial commencement expected in the second half of this year. They also said the Michael J. Fox Foundation grant of nearly USD 500,000 will be reflected in full-year results, and they continue to assess eligibility for an R&D tax incentive rebate.

David Stamler framed the quarter as a period of steady execution on ATH434, emphasizing regulatory preparation, manufacturing and preclinical work, and site/country feasibility for Phase II. He highlighted growing external validation, including conference interest, expert support, animal data showing reduced alpha-synuclein pathology and improved motor performance, and safety findings showing no cardiac liability at clinically tested doses. His tone was confident and expansionary, pointing to ATH434 as the priority while also discussing future growth through new compounds and PBT2 beyond neurology.

Kathryn Andrews said the half-year results were in line with expectations and budget, citing an $8.6 million operating loss and $7.3 million net operating cash outflow. She said cash was $35 million at December 31, boosted by a $35 million placement to Australian and international institutional and sophisticated investors, and noted the placement was fully subscribed. She said the proceeds are funding ATH434 clinical development, including bioMUSE and the planned Phase II trial in MSA, as well as ongoing research, discovery, and working capital.

In Q&A, management said ATH434 Phase II preparation is proceeding according to plan, with U.S. FDA feedback already received and European regulatory guidance expected in the near future. They said clinical trial site and country selection work is ongoing and still expect to start the trial in the second half of this year. On PBT2, they acknowledged the prior FDA partial clinical hold for Alzheimer’s development and said any future plan will need to address the earlier nonclinical findings; they also said a new AMR program could attract nondilutive funding, but the clinical path and market value have not yet been determined.